QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia 期刊论文 ACTA PHARMACEUTICA SINICA B, 2019, 卷号: 9, 期号: 6, 页码: 1216-1230 作者:  Wu, Chenglin;  Xi, Cong;  Tong, Junhua;  Zhao, Jing;  Jiang, Hualiang 收藏  |  浏览/下载：47/0  |  提交时间：2020/07/01 PCSK9  Tetrahydroprotoberberine derivatives  Low-density lipoprotein cholesterol  Lipid-lowering  PCSK9 expression  Low-density lipoprotein receptor  Total cholesterol  Hyperlipidemia hamster   PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol 期刊论文 MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 卷号: 19, 期号: 2, 页码: 165-176 作者:  Wang, Yan;  Liu, Zhao-Peng 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/11 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9)  low-density lipoprotein cholesterol (LDL-C)  low-density lipoprotein  receptor (LDLR)  cardiovascular disease (CVD)  hypercholesterolemia  alirocmab  evolocumab   Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis 期刊论文 2019, 卷号: 105, 期号: 15, 页码: 1149-1159 作者:  Du, Heyue;  Li, Xiaodan;  Su, Na;  Li, Ling;  Hao, Xiaoting 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 cardiovascular disease  low-density lipoprotein cholesterol  lipid-lowering drugs  proprotein convertase subtilisin  kexin type 9 inhibitors  systematic review   designsynthesisandbiologicalevaluationofnoveltetrahydroprotoberberinederivativesthpbsasproproteinconvertasesubtilisinkexintype9pcsk9modulatorsforthetreatmentofhyperlipidemia 期刊论文 actapharmaceuticasinicab, 2019, 卷号: 9, 期号: 6, 页码: 1216 作者:  Wu Chenglin;  Xi Cong;  Tong Junhua;  Zhao Jing;  Jiang Hualiang 收藏  |  浏览/下载：52/0  |  提交时间：2020/07/01 DOPAMINE D-1  BERBERINE  EXPRESSION  INHIBITORS  IDENTIFICATION  CHOLESTEROL  MUTATIONS  LDLR  PCSK9  Tetrahydroprotoberberine derivatives  Low-density lipoprotein cholesterol  Lipid-lowering  PCSK9 expression  Low-density lipoprotein receptor  Total cholesterol  Hyperlipidemia hamster   Indole alkaloid from Nauclea latifolia promotes LDL uptake in HepG2 cells by inhibiting PCSK9 期刊论文 Phytomedicine, 2018 作者:  Aggrey, Mike Okweesi;  Li, Hui-Hui;  Wang, Wen-Qiong;  Wang, Yiping;  Xuan, Li-Jiang 收藏  |  浏览/下载：34/0  |  提交时间：2019/03/13 Anti-hyperlipidemia  Nauclea Latifolia  Pcsk9  Sar  Indoloquinolizidine Alkaloids   Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367 期刊论文 2018, 卷号: 41, 期号: 4, 页码: E69-E69 作者:  Cao, Ye-Xuan;  Li, Jian-Jun 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 IDENTIFICATION OF NOVEL HUMAN PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS USING A CELL-BASED HIGH-THROUGHPUT SCREENING ASSAY 期刊论文 2017, 卷号: 263, 页码: E220-E221 作者:  Wang, Li;  Hong, Bin;  Wang, Xuelei 收藏  |  浏览/下载：12/0  |  提交时间：2020/01/04 IDENTIFICATION OF NOVEL HUMAN PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS USING A CELL-BASED HIGH-THROUGHPUT SCREENING ASSAY 会议论文 ATHEROSCLEROSIS, 2017-08-01 作者:  Wang, Li;  Hong, Bin;  Wang, Xuelei 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression 期刊论文 ACTA PHARMACOLOGICA SINICA, 2014, 卷号: 35, 期号: 8, 页码: 994-1004 作者:  Yan, Hong;  Ma, Yan-ling;  Gui, Yu-zhou;  Wang, Shu-mei;  Wang, Xin-bo 收藏  |  浏览/下载：19/0  |  提交时间：2019/01/08 cholesterol homeostasis  LDLR  MG132  proteasome inhibition  PKC  PCSK9  pravastatin  HepG2  cells